Arctic Bioscience – Clinical Trial Application for HRO350 Phase IIb - update
Reference is being made to the stock exchange release from 25 August 2022 regarding H1-2022 Reporting, where Arctic Bioscience announced that Clinical Trial Application (CTA) for a Phase IIb clinical trial in mild-to-moderate psoriasis with the investigational medicinal product (IMP) HRO350 was expected to be submitted in Q3 2022.
Arctic Bioscience is planning to send the CTA within 2 weeks. Approval of CTA by authorities will allow for the first patient to be enrolled in the Phase IIb clinical trial as planned in Q4 2022.
As previously communicated, sites for the clinical trial with access to sufficient number of patients to conduct the study are localized in five European countries.
The Clinical Trial Application contains key information about the IMP HRO350 and the planned clinical trial activities.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.